Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
NCT05248672
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Interventions
DRUG:
CT1812
Sponsor
Cognition Therapeutics